Ezra Cohen to Induction Chemotherapy
This is a "connection" page, showing publications Ezra Cohen has written about Induction Chemotherapy.
Connection Strength
0.889
-
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
Score: 0.145
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.112
-
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
Score: 0.111
-
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
Score: 0.099
-
The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7.
Score: 0.098
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
Score: 0.096
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.088
-
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021 03; 156:281-293.
Score: 0.044
-
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis. Cancer J. 2017 Mar/Apr; 23(2):79-83.
Score: 0.033
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.032
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.031